Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 MicroRNA family

Clinical Cancer Research

Volumn 14, Issue 8, 2008, Pages 2334-2340

  Motoyama, Kazuo ^a,b   Inoue, Hiroshi ^a   Nakamura, Yoshito ^a   Uetake, Hiroyuki ^b   Sugihara, Kenichi ^b   Mori, Masaki ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP A2 PROTEIN; MICRORNA; PROTEIN LET 7; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER SURVIVAL; CHROMATIN; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER;

FEMALE; HMGA2 PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICRORNAS; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; PROGNOSIS; RNA, MESSENGER; STOMACH NEOPLASMS;

EID: 42249103794     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4667     Document Type: Article

References (43)

1. Reeves R. Molecular biology of HMGA proteins: hubs of nuclear function. Gene 2001;277:63-81.
2. Hock R, Furusawa T, Ueda T, Bustin M. HMG chromosomal proteins in development and disease. Trends Cell Biol 2007;17:72-9.
3. Rogalla P, Drechsler K, Frey G, et al. HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am J Pathol 1996;149:775-9.
4. Sgarra R, Rustighi A, Tessari MA, et al. Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett 2004;574:1-8.
5. Zhou X, Benson KF, Ashar HR, Chada K. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 1995;376:771-4.
6. Weedon MN, Lettre G, Freathy RM, et al. A common variant of HMGA2 is associated with adult and childhood height in the general population. Nat Genet 2007;39:1245-50.
7. Bol S, Wanschura S, Thode B, et al. An endometrial polyp with a rearrangement of HMGI-C underlying a complex cytogenetic rearrangement involving chromosomes 2 and 12. Cancer Genet Cytogenet 1996;90:88-90.
8. Geurts JM, Schoenmakers EF, Van de Ven WJ. Molecular characterization of a complex chromosomal rearrangement in a pleomorphic salivary gland adenoma involving the 3′-UTR of HMGIC. Cancer Genet Cytogenet 1997;95:198-205.
9. Fedele M, Battista S, Manfioletti G, Croce CM, Giancotti V, Fusco A. Role of the high mobility group A proteins in human lipomas. Carcinogenesis 2001;22:1583-91.
10. Zaidi MR, Okada Y, Chada KK. Misexpression of full-length HMGA2 induces benign mesenchymal tumors in mice. Cancer Res 2006;66:7453-9.
11. Fedele M, Battista S, Kenyon L, et al. Over expression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 2002;21:3190-8.
12. Fedele M, Visone R, De Martino I, et al. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 2006;9:459-71.
13. Rogalla P, Drechsler K, Kazmierczak B, Rippe V, Bonk U, Bullerdiek J. Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: relationship to histologic grade. Mol Carcinog 1997;19:153- 6.
14. Sarhadi VK, Wikman H, Salmenkivi K, et al. Increased expression of high mobility group A proteins in lung cancer. J Pathol 2006;209:206-12.
15. Meyer B, Loeschke S, Schultze A, et al. HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog 2007;46:503-11.
16. Abe N, Watanabe T, Suzuki Y, et al. An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue. Br J Cancer 2003;89:2104-9.
17. Miyazawa J, Mitoro A, Kawashiri S, Chada KK, Imai K. Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res 2004;64:2024-9.
18. Belge G, Meyer A, Klemke M, et al. Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias. Genes Chromosomes Cancer 2008;47:56-63.
19. Shell S, Park SM, Radjabi AR, et al. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A 2007;104:11400-5.
20. Langelotz C, Schmid P, Jakob C, et al. Expression of high-mobility-group- protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer. Br J Cancer 2003;88:1406-10.
21. Caldas C, Brenton JD. Sizing up miRNAs as cancer genes. Nat Med 2005;11:712-4.
22. Esquela-Kerscher A, Slack FJ. Oncomirs-micro-RNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
23. Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000;403:901-6.
24. Lee YS, Kim HK, Chung S, Kim KS, Dutta A. Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation. J Biol Chem 2005;280:16635-41.
25. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64:3753-6.
26. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635-47.
27. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98.
28. Akao Y, Nakagawa Y, Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 2006;29:903-6.
29. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 2007;315:1576-9.
30. Hebert C, Norris K, Scheper MA, Nikitakis N, Sauk JJ. High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer 2007;6:5.
31. Wang T, Zhang X, Obijuru L, et al. A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer 2007;46:336-47.
32. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007;21:1025-30.
33. Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat Rev Cancer 2007;7:899-910.
34. Mimori K, Mori M, Shiraishi T, et al. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer 1997;76:531-6.
35. Mori M, Mimori K, Yoshikawa Y, et al. Analysis of the gene-expression profile regarding the progression of human gastric carcinoma. Surgery 2002;131:S39-47.
36. Inoue H, Mori M, Honda M, et al. The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma. Gastroenterology 1995;109:1522-5.
37. Ogawa K, Utsunomiya T, Mimori K, et al. Clinical significance of elongation factor-1δ mRNA expression in esophageal carcinoma. Br J Cancer 2004;91:282-6.
38. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
39. Yang S, Jeung HC, Jeong HJ, et al. Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer. Genomics 2007;89:451-9.
40. Fabjani G, Tong D, Wolf A, et al. HMGA2 is associated with invasiveness but not a suitable marker for the detection of circulating tumor cells in breast cancer. Oncol Rep 2005;14:737-41.
41. Hay ED. The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev Dyn 2005;233:706-20.
42. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005;17:548-58.
43. Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin CH, Moustakas A. Transforming growth factor-β employs HMGA2 to elicit epithelial- mesenchymal transition. JCell Biol 2006;174:175-83.